Our solutions:

Transcript for the CDC Telebriefing: Update on 2019 Novel Coronavirus (2019-nCoV)

Today, the U.S. Department of Health and Human Services and the U.S. Public Health Service (USPHS) published an updated <a href="https://www.cdc.gov/mmwr/volumes/69/rr/rr6904a1.htm?s_cid=rr6904a1_w">solid organ transplant guideline</a> to assess donors and monitor recipients for human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus infections.

The U.S. Centers for Disease Control and Prevention (CDC) is joining the global public health community to mark the end of the Ebola Virus Disease (Ebola) outbreak in the eastern part of the Democratic Republic of the Congo (DRC).

The research is based on the number of missed screenings, urgent referrals and delayed treatments.

The applause was inspired by the weekly Clap for Carers during the peak of the coronavirus lockdown.

An online portal will launch in England later this month to help people with ongoing symptoms.

<p dir="ltr"></p> <p dir="ltr">WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients.</p> <p dir="ltr">The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation. </p> <p dir="ltr">These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect. </p> <p dir="ltr">For each of the drugs, the interim results do not provide solid evidence of increased mortality. There were, however, some associated safety signals in the clinical laboratory findings of the add-on Discovery trial, a participant in the Solidarity trial. These will also be reported in the peer-reviewed publication. </p> <p dir="ltr">This decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19. The interim Solidarity results are now being readied for peer-reviewed publication.</p> <div><br></div> <div><br></div>

WHO provides this timeline of the organization’s COVID-19 response activities for general information. WHO will update the timeline on a regular basis and in light of evolving events and new information. Unless noted otherwise, country-specific information and data are as reported to WHO by its Member States. This timeline continues in the spirit of, and supersedes, the WHO Rolling Updates and the WHO Timeline statement published in April 2020. It is not intended to be exhaustive and does not contain details of every event or WHO activity. As of 29 June 2020, the following milestones and events focused on COVID-19 have taken place: • The Director-General and Executive Director of the WHO Health Emergencies Programme have held 74 media briefings. The Director-General's opening remarks, transcripts, videos and audio recordings for these media briefings are available online. • There have been 23 Member State Briefings and information sessions. • EPI-WIN, WHO’s information network for epidemics, has convened 60 technical webinars, making available 287 expert panellists to more than 13,500 participants, from more than 120 countries and territories, with representation from as many as 460 organizations. • The OpenWHO platform has had more than 2.7 million enrolments in its COVID-19 courses. Free training is available on 13 different topics translated into 31 languages to support the coronavirus response, for a total of 100 COVID-19 courses. • WHO’s landscape of COVID-19 candidate vaccines lists 17 candidate vaccines in clinical evaluation and 132 in preclinical evaluation. In addition to the selected guidance included below, all of WHO’s technical guidance on COVID-19 can be found online here. All events listed below are in the Geneva, Switzerland time zone (CET/CEST). Note that the dates listed for documents are based on when they were finalised and timestamped.

With this year’s Operation Transformation reaching its finale I wanted to catch up with the five leaders to find out more about their incredible journey.

Metabolic testing is widely available at gyms, universities and medical clinics - but just how accurate is it and will the data help you lose weight?

Thousands of women with the most deadly form of breast cancer could be given hope by a breakthrough treatment which could make chemotherapy effective.